Our Values
Message
Corporate Philosophy
Corporate Branding
Sawai at a Glance
Transparency
Products
Quality Policy & Feature of Each Function
ESG Data（Related Content）
Sustainability
Sustainability Initiatives
Our Approach
ESG Data
Integrated Report（Related Content）
Our Humanistic Business
Corporate Profile
Corporate History
Investors
Message for Our Investors
Corporate Philosophy（Related Content）
Stock Information
IR News
Financials
IR Reports
IR Schedule
Integrated Report
Disclosure Policy
Our humanistic business
Index
Top Message
Nov. 08. 2019
Sawai Reports First Half of FY2019 Financial Results
Oct. 08. 2019
Upsher-Smith Launches Tosymra™ (sumatriptan) Nasal Spray for the Acute Treatment of Migraine in Adults
Sep. 06. 2019
Upsher-Smith Launches Morphine Sulfate Tablets
Aug. 28. 2019
MHLW Approves Additional Indications for CANDESARTAN Tablets and OD Tablets2
Aug. 15. 2019
Sawai Receives Approvals for Two Generic Drugs with Five Strengths
Aug. 06. 2019
Sawai Reports First Quarter FY2019 Financial Results
Jul. 23. 2019
Sawai Selected for FTSE4Good and FTSE Blossom Japan Indexes
Jul. 22. 2019
Upsher-Smith Laboratories Completes Acquisition of Two Treatments for Acute Migraine in Adults
Jun. 21. 2019
Osteoporosis drug "Minodronic Acid Tablets 50 mg [SAWAI]" wins "World Star Awards" in a prestigious packaging contest.
Jun. 18. 2019
MHLW Approves Additional Indications for METHOTREXATE Capsules
Jun. 14. 2019
Upsher-Smith Laboratories Enters Into Agreement to Acquire Tosymra™ and Zembrace® Symtouch®
Jun. 13. 2019
Sawai Launches Three Generic Drugs with Seven Strengths
Jun. 05. 2019
MHLW Approves Additional Indication for LINEZOLID Injection and Tablets
May. 14. 2019
Sawai Reports FY2018 Financial Results
Mar. 28. 2019
Upsher-Smith Launches Generic Version of Prozac® (Fluoxetine) Tablets
Mar. 27. 2019
MHLW Approves New Indication for DONEPEZIL Tablets, OD Tablets and Fine Granules
Mar. 06. 2019
MHLW Approves New Indication for ARIPIPRAZOLE Tablets and Oral Solution
Feb. 20. 2019
Upsher-Smith Laboratories, LLC celebrates its 100-year anniversary.
Feb. 15. 2019
Sawai Receives Approvals for Three Generic Drugs with Six Strengths
Feb. 14. 2019
Sawai Reports Third Quarter FY2018 Financial Results
Feb. 13. 2019
An interview with Mitsuo Sawai (President of Sawai Pharmaceutical Co., Ltd.) was published in 2019 Japan Business Report in the South China Morning Post.
Jan. 09. 2019
MHLW Approves New Indication for ARGATROBAN Injection
Dec. 13. 2018
Sawai Launches Six Generic Drugs with 14 Strengths
Dec. 05. 2018
MHLW Approves New Indication for RISEDRONATE Tablets and DOBUTAMINE I.V. Infusion
